Biotech | November 18, 2021
AstraZeneca’s Covid-19 drug offers 83% protection over six months
Six-months follow-up of prevention trial showed 83% reduced risk of symptomatic Covid-19, with no severe disease or deaths
Six-months follow-up of prevention trial showed 83% reduced risk of symptomatic Covid-19, with no severe disease or deaths
Branded and unbranded versions of the first-ever interchangeable biosimilar in the U.S. provide more affordable options for the millions of Americans living with diabetes
The cream has an estimated market size of US $ 28 million for twelve months ending Jun 2021 according to IQVIA
Launching in 2022, its availability will be expanded to the global market
Vakrangee’s distribution network across rural India will help penetrate underserved markets
The group now has 324 approvals and has so far filed over 400 ANDAs
The company performed particularly well in operational eco-efficiency, environmental and social reporting
The 50,000 square foot expansion will house a high-speed filling line and lyophilizers, which will increase the facility’s sterile injectable capacity by 50%
The interim data combines three mRNAs into one therapy injected directly into the tumour
Aster DM Healthcare announced its financial results for the quarter ended September 30, 2021
Subscribe To Our Newsletter & Stay Updated
